Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor

Burghaus, Stefanie; Halmen, Sonja; Gaß, Paul; Mehlhorn, Grit; Schrauder, Michael G.; Lux, Michael P.; Renner, Stefan P.; Beckmann, Matthias W.; Hein, Alexander; Thiel, Falk

doi:10.1007/s00404-015-3993-6

Cited by 24 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A percentage range of 40-46 and 30-45% has been reported for leiomyosarcomas carcinosarcomas, respectively. In contrast to these findings, the range and percentage was estimated to 86-97% for ESSs and to 69% for adenosarcomas, respectively (20,(26)(27)(28). The rates reported in the present study were lower than those previously published.…”

Section: Uterine Sarcomas By Histological Type ----------------------contrasting

confidence: 99%

“…A German study of 143 women demonstrated that 12% of carcinosarcomas were from patients who were smokers, whereas this percentage was increased to 16% in leiomyosarcomas and to 28% in ESSs. A lower OS was noted in smokers (20).…”

Section: Discussionmentioning

confidence: 78%

“…It is important to note that 62% of these cases also received adjuvant therapy, which was not associated with the histological type. However, it has been reported that additional therapeutic interventions may yield controversial results (20,24). In the present study, only 1 out of 21 patients treated primarily with radiotherapy and/or chemotherapy without surgery, exhibited a satisfactory clinical response, highlighting the poor response of these cases to the standard radiotherapy treatment, which has been previously shown (14,21,25).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases

et al. 2020

View full text Add to dashboard Cite

The present study aimed to assess the diagnosis, treatment and follow-up of uterine sarcoma cases. A retrospective cohort study with 122 women recruited between 2001 and 2016 was performed. The data regarding epidemiology, clinical presentation, treatment and follow-up were analyzed based on the following histological types: Carcinosarcoma, leiomyosarcoma, endometrial stromal sarcoma (ESS) and adenosarcoma. Statistical analysis included descriptive statistics, logistic regression and survival curves. The diagnosis of uterine sarcoma exhibited an increasing trend of +1.2 new cases every 2 years (P=0.044) and comprised 10% of all uterine cancer diagnoses. There were 47% carcinosarcomas, 22% leiomyosarcomas, 16% ESS and 14% adenosarcomas. The majority of the women was ≥60 years old (62%). Among the subjects, 77% were postmenopausal, 61% had a body mass index up to 29.9 kg/m 2 and 71% presented with a comorbidity. Regression analysis exhibited an association between post menopause and the histological type associated with lower overall survival (OS), namely leiomyosarcoma or carcinosarcoma (odds ratio, 5.45, P<0.001). Stage I malignancy was present in 44% and Stage IV in 22%. The treatment included primary surgery in 78% of the cases, whereas 79% received adjuvant therapy. Only 55 cases achieved disease control and 20 relapsed (36%) with a 5-year OS rate of 33%. The OS was lower for carcinosarcoma and leiomyosarcoma (20%; P=0.003). In summary, the present study indicated that the number of uterine sarcoma cases had increased between 2001 and 2016. The majority of the women were >60 years old and diagnosed in advanced stages. The postmenopausal status was associated with histological types of poor prognosis. The OS was low and worse for patients with carcinosarcoma and leiomyosarcoma.

show abstract

Section: Uterine Sarcomas By Histological Type ----------------------contrasting

confidence: 99%

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These results were also confirmed in different analyses from hospital series. 13,14 However, high-grade ESSs are rare tumors, and both the undifferentiated uterine sarcoma and its low-grade counterpart might be a challenging differential diagnosis for pathologists. According to the WHO Classification of Tumours of Female Reproductive Organs, we classified sarcoma with ICD-O-3 code 8930/3 as high-grade ESS (UES).…”

Section: Discussionmentioning

confidence: 99%

Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women

Pietzner

Buttmann-Schweiger

Sehouli

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…There are numerous histological subtypes, and it is general consensus that the most common histological subtype is leiomyosarcoma (LMS), accounting for 60-70% of all cases, followed by endometrial stromal sarcoma (ESS), ~15-20% cases, worldwide (2). However, in Japan, carcinosarcoma (CS) represents 46% of uterine sarcoma diagnoses, followed by LMS (36%) and then ESS (13%) (3).…”

Section: Introductionmentioning

confidence: 99%

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

et al. 2018

View full text Add to dashboard Cite

Abstract. Uterine sarcomas are some of the most malignant and aggressive tumor types among the gynecologic malignancies, and they are associated with a high rate of recurrence and a poor prognosis. Due to their rarity and diversity, the optimal treatment for recurrent uterine sarcomas has not yet been elucidated. The aim of the present study was to investigate the potential of secondary cytoreductive surgery (SCS) for patients with recurrent uterine sarcomas. A total of 18 patients with recurrent uterine sarcomas were retrospectively identified at the

show abstract

Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor

Abstract: Adjuvant therapy has so far not shown any overall survival benefit, and the focus is therefore on primary surgery. In future studies, the entities should be investigated separately in relation to prognostic factors and effective therapeutic management.

Cited by 24 publications

References 39 publications

Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases

Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases

Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women

Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas

Contact Info

Product

Resources

About